← All Cytomx Therapeutics, INC filings

Cytomx Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CTMX
Cytomx Therapeutics, INC
DEFA14A: CytomX Therapeutics Files Definitive Proxy Statement
CytomX Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
CTMX
Cytomx Therapeutics, INC
DEF: CytomX Therapeutics to Hold Annual Stockholders Meeting on June 11, 2025, to Vote on Director Elections, Auditor Ratification, and Equity Incentive Plan Amendment
CytomX Therapeutics is convening its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, and approval of an amended equity incentive plan.
NASDAQ
CTMX
Cytomx Therapeutics, INC
DEFA14A: CytomX Therapeutics Seeks Stockholder Approval to Double Authorized Common Stock
CytomX Therapeutics is supplementing its proxy statement to clarify the number of authorized common shares available for issuance, seeking approval to increase the total from 150 million to 300 million shares.
NASDAQ
CTMX
Cytomx Therapeutics, INC
DEFA14A: CytomX Therapeutics, Inc. Files Definitive Proxy Statement
CytomX Therapeutics, Inc. has filed a definitive proxy statement with the SEC related to its upcoming shareholder meeting.
NASDAQ
CTMX
Cytomx Therapeutics, INC
DEF 14A: CytomX Therapeutics Seeks Stockholder Approval for Share Increase, Director Elections at 2024 Annual Meeting
CytomX Therapeutics is holding its 2024 Annual Meeting of Stockholders on May 15, 2024, to vote on director elections, auditor ratification, an increase in authorized common stock, and executive compensation.